Biosig Technologies Inc (BSGM)

[mick]

looks good/ BioSig Technologies Inc. (OTCQB: BSGM)

In recent news January 11th, 2017 BioSig Tech was featured in
The Journal of the American College of Cardiology (JACC)

The article entitled Novel Electrophysiology Signal Recording System Enables Specific Visualization of the Purkinje Network and Other
High-Frequency Signals highlights the potential benefits of using BioSig’s PURE EP System compared to a standard recording system.

The study was completed by the team led by Dr. Samuel Asirvatham at Mayo Clinic in Rochester, Minnesota.

About JACC Journals

The Journal of the American College of Cardiology program is the
best read cardiovascular journal program worldwide, with an international reputation for excellence.

JACC is consistently rated the number one benefit of membership in
the American College of Cardiology,
and maintains the highest Impact Factor in the area of cardiovascular medicine.

The JACC journals publish peer-reviewed articles on all aspects of cardiovascular disease, including original clinical studies, translational investigations with clear clinical relevance,
state-of-the art papers, review articles,
and editorials interpreting and commenting on the research presented. Read the full release-

http://finance.yahoo.com/news/biosig-technologies-pure-ep-system-130000374.html

Highlights

On the road to achieving FDA 501(k) clearance this year,
BioSig has already achieved a number of milestones,
indicating a high degree of efficacy of the platform in tests
completed in a number of prestigious cardiac centers around the country.

A series of milestones in the coming quarters should foster considerable recognition of BioSig’s prospects,
driving market value of the Company’s shares.

These include the results of recent and future preclinical studies,
the filing for FDA 510(k) clearance to market its platform,
and an up-list to NASDAQ.

The Company has collaborated with the leading cardiac centers in the country.

The Mayo Clinic, UCLA Cardiac Arrhythmia Center,
Mount Sinai Medical are just a few of the prestigious institutions
that have participated in the development of the PURE EP™ platform.

BioSig’s leadership team rivals that of health care companies
generating hundreds of millions in annual sales. The team members
have a history of clinical, corporate, financial, and operational successes.

Management team and bio's here- https://biosigtech.com/about-us/management-team/